Main > > >CARDIOVASCULAR. *

---

Cardio.>CardioVascular Disease (CVD). Prognostic Device.
Availability: AT; CA; CH; DE; IN & UK
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 07.17.




Cardio.>CardioVascular Implantable Electronic Device. (CIED). Remote Monitoring Software.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 09.08.




Cardio.>HyperTriGlyceridemia. (HTG). Icosapent Ethyl [Ethyl EicosaPentaenoic Acid (E-EPA)]. Indications:
Indication (1): HTG>Treat.>Diet+ Icosa-
pent Ethyl Capsules.
Indication (2): CardioVascular (CV)
Events (in Adult Pa-
tients with HTG & CV
DIS. or Diabetes) RISK
Reduction: Statin+Icosa-
pent Ethyl Capsules.
CV Events:
- Coronary Revascularization.
- Myocardial Infarction (MI)
- Stroke
- Unstable Angina requiring hospitali-
zation.
CA Approval Date (2): 2020. 01.02.
USA Approval Date (1): 2012.
USA Approval Date (2): 2019. 12.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.03.




Critical Care Medicine>Blood Coagulation Point Of Care (POC) Status Hemostasis DIAG. System.
Technology uses UltraSound ..
EU Approval Date : 2019. 09.10>
>Liver & Trauma Surgeries
USA Approval Date: 2019. 03.13>
>CardioVascular (CV) & Orthopedic Surge
ries.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 10.17.




Critical Care Medicine>HyperKalemia. TREAT.: Na Zr CycloSilicate.
- Cardiovascular:
risk of hyperkalaemia increases for
patients who take common medications
for heart failure (HF), such as renin-
angiotensin-aldosterone system (RAAS)
inhibitors, which can increase
potassium in the blood.
- Metabolic.
- Renal (Nephrology):
risk of hyperkalaemia increases
significantly for patients with
chronic kidney disease (CKD)
EU Approval Date: 2018. 03.22.
USA Approval Date: 2018. 05.18.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 05.22.




>CARDIOVASCULAR. *'s products
This section has no products